Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Source: SeekingAlpha
2025-12-10 13:43:43 ET
More on Dyne Therapeutics, Avidity Biosciences
- Dyne Therapeutics: Why The $350M Public Offering Was Critical
- Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript
- Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy - Slideshow
- Dyne Therapeutics prices $350 stock offering
- Dyne Therapeutics announces $300M proposed public offering
Read the full article on Seeking Alpha
For further details see:
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Avidity Biosciences Inc.
NASDAQ: RNA
RNA Trading
-0.65% G/L:
$13.86 Last:
103,774 Volume:
$13.77 Open:
RNA Latest News
February 27, 2026 09:19:00 am
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
February 26, 2026 04:02:00 pm
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 23, 2026 08:00:00 am
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
RNA Stock Data
$10,978,987,941
124,608,839
0.38%
98
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
